A blood-based biomarker panel that includes DNA and protein markers featured a 71% sensitivity at 90% specificity for the detection of early-stage hepatocellular carcinoma (HCC)
Read more
Home ยป
The indication for nivolumab (Opdivo) as monotherapy for hepatocellular carcinoma (HCC) for patients previously treated with sorafenib has been voluntarily withdrawn by the manufacturer, Bristol-Myers
Read more
With the novel immunotherapy tislelizumab, durable responses are achieved for patients with advanced hepatocellular carcinoma (HCC), regardless of the number of prior lines of therapy,
Read more
NEW YORK (Reuters Health) – Drugs targeting the MAGEA3 gene may help keep low-grade liver tumors from progressing to high-grade, researchers say. “We were surprised
Read more